CA
NZ
UK
AU
IND
US
BioStem Technologies, Inc. (OTC:BSEM) closed out a pivotal stretch in early July 2026, winning four new U.S. design patents for its placental allograft technology and filing a Form 10 registration statement with the SEC. The Pompano Beach, Florida regenerative-medicine company is chasing a Nasdaq …
Boston Scientific Corporation (NYSE:BSX) has agreed to buy thrombectomy specialist Penumbra in a cash-and-stock deal valued at roughly $14.5 billion in enterprise value. The transaction, awaiting Penumbra shareholder approval and customary closing conditions, would add scaled clot-removal technology to a cardiovascular business already growing …
ARS (NASDAQ:SPRY) Pharmaceuticals is scaling U.S. sales of neffy, the first needle-free epinephrine nasal spray, even after CVS Caremark did not add the product to its commercial formulary for the July 1, 2026 cycle. First-quarter 2026 net product revenue reached $17.5 million, pediatric access …
Actuate Therapeutics, (NASDAQ:ACTU) a clinical-stage biopharmaceutical company built around the GSK-3β inhibitor elraglusib, reported statistically significant overall-survival data from a randomized Phase 2 pancreatic-cancer trial in January 2026 and is working to translate earlier pediatric-cancer signals in Ewing sarcoma and neuroblastoma into a registration-directed …
Akebia (NASDAQ:AKBA) Therapeutics and U.S. Renal Care stopped the VOICE trial early in June 2026 after an interim look showed Vafseo cut hospitalizations significantly versus a standard anemia drug, a result the companies called overwhelming. Layered on a still-loss-making Vafseo launch and fading Auryxia …
Aldeyra (NASDAQ:ALDX) Therapeutics is regrouping after a third Complete Response Letter for reproxalap in dry eye disease, delivered March 17, 2026. With a Type A meeting request in motion, roughly $65 million in cash, an unexercised AbbVie licensing option, and a broader immune-disease pipeline …
Anavex Life Sciences Corp. (NASDAQ:AVXL) enters the second half of 2026 rebuilding its executive suite while absorbing a withdrawn European marketing application for blarcamesine, its lead Alzheimer's candidate. A departed CEO, an interim successor, a delinquent quarterly filing and a Nasdaq compliance notice have …
Arcturus Therapeutics (NASDAQ:ARCT) has enlisted Thermo Fisher Scientific to help manufacture and eventually commercialize ARCT-032, its inhaled mRNA candidate for cystic fibrosis, ahead of a planned Phase 3 program. The San Diego company, whose approved KOSTAIVE COVID-19 vaccine is commercialized through partners, reported shrinking …
Akari Therapeutics, Plc (NASDAQ:AKTX) has entered a preclinical research collaboration with Whitehawk Therapeutics to test whether its RNA-splicing payload, PH1, can be combined with Whitehawk's topoisomerase I inhibitor ADC platform. Announced July 21, 2026, the deal arrives as Akari pushes its lead candidate, AKTX-101, …
MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage neuroscience company in Redwood City, California, listed on the Nasdaq Global Select Market in October 2025. Its shares fell 72.91% in a single regular session on Monday, closing at $9.90 against a previous close of $36.56. The move …
Please wait processing your request...